TIS Management has copped its fair share of criticism in recent...

TIS Management has copped its fair share of criticism in recent weeks over delays associated to CE Marking and fair enough to some degree.

HC should be all about balanced views and opinions, I for one remain content that the CE mark is literally around the corner as will be the commencement of Vitrogro sales but more importantly imo the real true value of TIS is well into the future.. Why ?

"It is estimated that more than 360 million people worldwide have diabetes and this number is expected to increase by more than 50% by 2030.

People with diabetes are particularly prone to diabetic limb and foot infections due to insufficient blood flow and impaired wound healing.

Standard oral or intravenous delivery of antibiotics is often ineffective in these patients because dosage levels cannot be achieved at a sufficient level at the site of the limb infection.

Infections of the lower limb are the leading cause of amputations globally, which leads to increased rates of hospitalisation and higher healthcare costs throughout the developed world."

Vitrogro will be one of the most exciting and effective treatments that will address impaired wound healing.

As some are solely focused on thinking how deep there pockets may become in coming weeks spare a moment to think about how sufferers of impaired wounds or amputations feel and the angst at the possibility of having a new treatment available in days or weeks.

Being part of TIS as a shareholder is the higher reward